Evidence map›Paper›PMID 32971126›Full record

ArticleThe Journal of investigative dermatology2021

5'-Cap‒Dependent Translation as a Potent Therapeutic Target for Lethal Human Squamous Cell Carcinoma.

Ritesh Kumar Srivastava, Jasim Khan, Aadithya Arumugam, Suhail Muzaffar, Purushotham Guroji, Marina S Gorbatyuk, Craig A Elmets, Andrzej T Slominski, M Shahid Mukhtar, Mohammad Athar

Open access · greenAbstract read
In one paragraph

Article in The Journal of investigative dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ritesh Kumar SrivastavaUAB Research Center of Excellence in Arsenicals and Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Jasim KhanUAB Research Center of Excellence in Arsenicals and Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Aadithya ArumugamUAB Research Center of Excellence in Arsenicals and Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Suhail MuzaffarUAB Research Center of Excellence in Arsenicals and Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Purushotham GurojiUAB Research Center of Excellence in Arsenicals and Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Marina S GorbatyukDepartment of Optometry and Vision Science, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Craig A ElmetsUAB Research Center of Excellence in Arsenicals and Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama, USA; Laboratory Service of the Veteran Administration Medical Center, Birmingham, Alabama, USA.
Andrzej T SlominskiUAB Research Center of Excellence in Arsenicals and Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama, USA; Laboratory Service of the Veteran Administration Medical Center, Birmingham, Alabama, USA.
M Shahid MukhtarDepartment of Biology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Mohammad AtharUAB Research Center of Excellence in Arsenicals and Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama, USA. Electronic address: mohammadathar@uabmc.edu.
University of Alabama at Birmingham · USUniversity of Alabama at Birmingham Hospital · US

Funding

Mechanism of action and function of novel secosteroid 20(OH)D3 in the skinR01AR073004 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ANDRZEJ T SLOMINSKI · 2018 to 2026
$2.9M
Chemoprevention of environmental UVB-induced skin cancer in immunosuppressed miceR01ES026219 · NIEHS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ATHAR, MOHAMMAD · 2016 to 2020
$1.7M
Significance of metabolic activation of lumisterol in the skinR01AR071189 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SLOMINSKI, ANDRZEJ T · 2017 to 2021
$1.6M
CYP11A1-derived secosteroids as therapeutic agents in UVB induced skin cancerI01BX004293 · VA · BIRMINGHAM VA MEDICAL CENTER · PI SLOMINSKI, ANDRZEJ T · 2019 to 2025
–
BLRD VA I01 BX004293NIAMS NIH HHS R01 AR071189NIAMS NIH HHS R01 AR073004NIEHS NIH HHS R01 ES026219
6 · The paper itself

Abstract

Skin squamous cell carcinomas (SCCs) are a major cause of death in patients who have undergone or will undergo organ transplantation. Moreover, these neoplasms cause significant disease and economic burden and diminish patients' life quality. However, no effective treatment or intervention strategies are available. In this study, we investigated the pathologic role of 5'-cap translation, which is regulated by the formation of a ternary initiation factor complex involving eIF4E, eIF4G, and eIF4A1. We detected increased expression of phosphorylated eIF4E, eIF4G, and eIF4A1 in human and murine skin SCCs. The increase in these ternary initiation factor complex proteins was associated with enhanced eIF4E translation targets cyclin D1 and c-Myc. Conversely, small interfering RNA-mediated depletion of eIF4E in human SCC cells (A431 and SCC-13) reduced eIF4G and proteins that regulate the cell cycle and proliferation. Notably, inhibition of Raf/MAPK/extracellular signal-regulated kinase signaling decreased eIF4E and phosphorylated eIF4E accumulation and significantly diminished cell-cycle gene expression and tumor volume of A431-derived xenograft tumors. Furthermore, disrupting the eIF4E with an allosteric inhibitor of eIF4E and eIF4G binding, 4EGI-1, decreased the eIF4E/eIF4G expression and reduced the proliferation. Finally, combined inhibition of the Raf/MAPK/extracellular signal-regulated kinase axis and eIF4E impaired 5'-cap‒dependent translation and abrogated tumor cell proliferation. These data demonstrate that 5'-cap‒dependent translation is a potential therapeutic target for abrogating lethal skin SCCs in patients who have undergone or will undergo organ transplantation.

Indexed as

Allosteric RegulationAnimalsCarcinoma, Squamous CellCell CycleCell Line, TumorCell ProliferationCyclin D1Eukaryotic Initiation Factor-4AEukaryotic Initiation Factor-4EEukaryotic Initiation Factor-4GGene Expression Regulation, NeoplasticHumansMAP Kinase Signaling SystemMicePeptide Chain Initiation, TranslationalPhosphorylationCyclin D1Eukaryotic Initiation Factor-4AEukaryotic Initiation Factor-4EEukaryotic Initiation Factor-4GProto-Oncogene Proteins c-mycRNA CapsRNA, Small Interfering

Identifiers

PMID32971126
PMCPMC7981283
OpenAlexW3087289752

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.